Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/08/2003WO2003037266A2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003WO2003037258A2 Methods and compositions for the treatment and diagnosis of pain disorders using 2047
05/08/2003WO2003037257A2 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
05/08/2003WO2003037253A2 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
05/08/2003WO2003037164A2 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
05/08/2003WO2003037060A2 Compositions and methods for wt1 specific immunotherapy
05/08/2003WO2003023404A8 A method of diagnosis and treatment and agents useful for same
05/08/2003WO2003020254A8 Pharmaceutical composition comprising (-)-secoisolariciresinol
05/08/2003WO2003014322A3 Proteins associated with cell growth, differentiation, and death
05/08/2003WO2003014128A3 Tumour inhibiting cerium compounds
05/08/2003WO2003012105A3 Vegf isoform
05/08/2003WO2003011224A3 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
05/08/2003WO2003011217A3 Grifola extracts and methods of use thereof
05/08/2003WO2003010308A3 Control of gene expression
05/08/2003WO2003009805A3 Analgesic methods using endothelin receptor ligands
05/08/2003WO2003006634A3 Use of oxidised lipoproteins for differentiation of precursor cells into mature dendritic cells
05/08/2003WO2003005955A3 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
05/08/2003WO2003002595A3 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
05/08/2003WO2003000633A3 A process for the isolation of a major harmful oxidant from cigarette smoke
05/08/2003WO2002098482A3 System for osmotic delivery of pharmaceutically active agents
05/08/2003WO2002098368A3 Mutant forms of cholera holotoxin as an adjuvant
05/08/2003WO2002094836A3 Methods for preparation and use of psorospermin analogs
05/08/2003WO2002085414A3 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
05/08/2003WO2002081499A3 Somatostatin agonists
05/08/2003WO2002079222A3 Fusion proteins for specific treatment of cancer and auto-immune diseases
05/08/2003WO2002072608A3 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
05/08/2003WO2002060897A3 Process for making substituted 8-arylquinolinium benzenesulfonate
05/08/2003WO2002057299A3 Vegfr-3 binding peptides and their use for inhibiting angiogenesis
05/08/2003WO2002057226A3 68730 and 69112 protein kinase molecules and uses therefor
05/08/2003WO2002039953A9 Texaphyrin coordination compounds and uses thereof
05/08/2003WO2002036110A3 Oral self-emulsifying formulations of pyranone protease inhibitors
05/08/2003WO2002026946A3 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
05/08/2003WO2002024226A9 Photosensitisers
05/08/2003WO2002020768A9 Caveolin peptides and their use as therapeutics
05/08/2003WO2002010216A3 Proteins and nucleic acids encoding same
05/08/2003WO2002008194A8 Novel heteroaryl derivatives and the use thereof as pharmaceuticals
05/08/2003WO2001091763A9 Extracts from spermatophyte plants with antitumor activity
05/08/2003WO2001082899A9 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030088101 E-ring expanded camptothecin derivatives
05/08/2003US20030088099 Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
05/08/2003US20030088092 Water-soluble porphyrin derivatives and methods of their preparation
05/08/2003US20030088085 MPROT12 polynucleotides and methods thereof
05/08/2003US20030088061 Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing an allosteric regulatory site
05/08/2003US20030087964 Method and pharmaceutical composition for the treatment of cancer
05/08/2003US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
05/08/2003US20030087956 Useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor alpha 4 beta 1.
05/08/2003US20030087952 17-Beta-hydroxysteroid dehydrogenase-II inhibitors
05/08/2003US20030087950 New alpha-amino acid sulphonyl compounds
05/08/2003US20030087947 Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photodynamic therapy
05/08/2003US20030087945 Sulfonylaminocarboxylic acids
05/08/2003US20030087934 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
05/08/2003US20030087924 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
05/08/2003US20030087923 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
05/08/2003US20030087922 Aryl substituted 2-aminopyrimidines and 2-aminopyridines
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087908 Substituted triazinyl amide derivatives and methods of use
05/08/2003US20030087907 Quinoline derivatives and quinazoline derivatives having azolyl group
05/08/2003US20030087906 Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
05/08/2003US20030087902 Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
05/08/2003US20030087901 Compounds and methods for modulation of estrogen receptors
05/08/2003US20030087900 Treating cancer, especially leukemia and breast cancer, by administering a compound that inhibits the expression of the TPT1 gene, such as hydroxyzine or promethazine.
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087895 Fused imidazole derivatives as multidrug resistance modulators
05/08/2003US20030087890 Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide
05/08/2003US20030087888 Anticancer agents
05/08/2003US20030087882 Antiinflammatory agents
05/08/2003US20030087873 Treating a Flaviviridae, Orthomyxoviridae or Paramyxoviridae infection
05/08/2003US20030087872 Fucosidase 32616 is differentially expressed in tumor and/or angiogenic tissue samples as compared to normal tissue samples
05/08/2003US20030087866 Suppression of malignancy utilizing ribonucleotide reductase R1
05/08/2003US20030087861 Administering mixture of antibody and drug; cancer sensitivity
05/08/2003US20030087846 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
05/08/2003US20030087842 Indolocarbazole anticancer agents and methods of using them
05/08/2003US20030087839 Combined preparations comprising morpholine anthracyclines and anticancer agent
05/08/2003US20030087837 Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
05/08/2003US20030087836 Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
05/08/2003US20030087832 Anticancer agents; antidiabetic agents, anticholesterol agents, cardiovascular disorders, osteoporosis
05/08/2003US20030087817 Regulation of endogenous gene expression in cells using zinc finger proteins
05/08/2003US20030087816 Anticancer, antitumor agents; genetic engineering
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087789 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
05/08/2003US20030087412 Nucleotide sequences coding polypeptide for use in the prevention and treatment of tumors, nervous system, cardiomyopathy, viral and metabolic diseases
05/08/2003US20030087408 Protein for use in the treatment of tumors
05/08/2003US20030087393 Endostatin for use in the treatment of cancer and tumor metastasis
05/08/2003US20030087378 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
05/08/2003US20030087377 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
05/08/2003US20030087340 Novel human leucine-rich repeat containing protein expressed predominately in nervous system tissues, HLRRNS1
05/08/2003US20030087317 Human NIM1 kinase
05/08/2003US20030087266 IGs as modifiers of the p53 pathway and methods of use
05/08/2003US20030087264 Detection of regulatory response to pulsatile electromagnetic stimulus; obtain tissue sample, insert probe, apply pulsatile stimulus, detect gene expression, classify genes which are expresed
05/08/2003US20030087252 Novel compositions and methods in cancer associated with altered expression of PRDM11
05/08/2003US20030087230 L-Ribo-LNA analogues
05/08/2003US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated
05/08/2003US20030086965 Combination chemotherapy
05/08/2003US20030086941 For diagnosing and therapy of gastrin-dependent tumor
05/08/2003US20030086933 Therapeutic systems
05/08/2003US20030086930 Administering CTLA-4 (cytotoxic T lymphocyte antigen-4) antibodies for therapy of cancer
05/08/2003US20030086919 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
05/08/2003US20030086914 Method and device for inducing biological processes by micro-organs
05/08/2003US20030086911 Methods and compositions for the stimulation of human immunodeficiency virus-specific cytotoxic T lymphocytes employing autologous antigen-peripheral blood mononuclear cells
1 ... 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 ... 2211